Skip to content

Study · Randomized controlled trial · 2025

7 results

RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.

Mashayekhi M, Safa BI, Nian H, Devin JK, Gamboa JL, Yu C, Chen R, Beckman JA, Koethe JR, Silver HJ, Niswender K, Luther JM, Brown NJ

The Journal of endocrinology23 Oct 2025Cited by 3 (Europe PMC)

PMID41042549 (opens in a new tab)PMCIDPMC12556785 (opens in a new tab)DOI10.1530/joe-25-0174 (opens in a new tab)PepBankPUB-41042549
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and pre-diabetes, weight loss on liraglutide was greater with each copy of the GLP-1R rs6923761 variant allele, a gene dose effect.

    In plain wordsIn adults with obesity and pre-diabetes, people with more copies of the GLP-1 receptor variant lost more weight on liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseWeight loss on liraglutide by rs6923761 allele count
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found significantly greater weight loss to liraglutide with each copy of the variant allele present, indicating a gene dose effect.
    1 context sentence
    Summary · context
    Here, we performed a pre-specified analysis of a randomized-controlled trial in individuals with obesity and pre-diabetes comparing treatment with the GLP-1R agonist liraglutide, the dipeptidyl peptidase 4 inhibitor sitagliptin or hypocaloric diet, and evaluated the effects of the rs6923761 variant on outcomes.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and pre-diabetes, carriers of the rs6923761 variant allele had a significant reduction in plasminogen activator inhibitor-1 after liraglutide treatment.

    In plain wordsIn adults with obesity and pre-diabetes, carriers of the GLP-1 receptor variant had a clear fall in plasminogen activator inhibitor-1 after liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasminogen activator inhibitor-1 after liraglutide in variant carriers
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, individuals with the variant allele exhibited a significant reduction in the pro-thrombotic and pro-inflammatory factor plasminogen activator inhibitor-1 after liraglutide treatment.
    1 context sentence
    Summary · context
    Here, we performed a pre-specified analysis of a randomized-controlled trial in individuals with obesity and pre-diabetes comparing treatment with the GLP-1R agonist liraglutide, the dipeptidyl peptidase 4 inhibitor sitagliptin or hypocaloric diet, and evaluated the effects of the rs6923761 variant on outcomes.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and pre-diabetes, the rs6923761 genotype had no effect on fasting glucose after liraglutide treatment.

    In plain wordsIn adults with obesity and pre-diabetes, the GLP-1 receptor variant did not change fasting glucose after liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeEffect of genotype on fasting glucose after liraglutide
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no effect of genotype on fasting glucose after liraglutide treatment
    1 context sentence
    Summary · context
    Here, we performed a pre-specified analysis of a randomized-controlled trial in individuals with obesity and pre-diabetes comparing treatment with the GLP-1R agonist liraglutide, the dipeptidyl peptidase 4 inhibitor sitagliptin or hypocaloric diet, and evaluated the effects of the rs6923761 variant on outcomes.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and pre-diabetes, rs6923761 variant carriers had decreased responsiveness of fasting insulin to liraglutide and hypocaloric diet.

    In plain wordsIn adults with obesity and pre-diabetes, carriers of the GLP-1 receptor variant had a weaker fasting insulin response to liraglutide and diet.

    Peptide
    Liraglutide
    Outcome
    DecreaseResponsiveness of fasting insulin to liraglutide by genotype
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    individuals with the variant allele exhibited decreased responsiveness to liraglutide and hypocaloric diet in measurements of fasting insulin, C-peptide, glucagon, and HOMA-IR
    1 context sentence
    Summary · context
    Here, we performed a pre-specified analysis of a randomized-controlled trial in individuals with obesity and pre-diabetes comparing treatment with the GLP-1R agonist liraglutide, the dipeptidyl peptidase 4 inhibitor sitagliptin or hypocaloric diet, and evaluated the effects of the rs6923761 variant on outcomes.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and pre-diabetes, rs6923761 variant carriers had decreased responsiveness of C-peptide to liraglutide and hypocaloric diet.

    In plain wordsIn adults with obesity and pre-diabetes, carriers of the GLP-1 receptor variant had a weaker C-peptide response to liraglutide and diet.

    Peptide
    Liraglutide
    Outcome
    DecreaseResponsiveness of C-peptide to liraglutide by genotype
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    individuals with the variant allele exhibited decreased responsiveness to liraglutide and hypocaloric diet in measurements of fasting insulin, C-peptide, glucagon, and HOMA-IR
    1 context sentence
    Summary · context
    Here, we performed a pre-specified analysis of a randomized-controlled trial in individuals with obesity and pre-diabetes comparing treatment with the GLP-1R agonist liraglutide, the dipeptidyl peptidase 4 inhibitor sitagliptin or hypocaloric diet, and evaluated the effects of the rs6923761 variant on outcomes.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and pre-diabetes, rs6923761 variant carriers had decreased responsiveness of glucagon to liraglutide and hypocaloric diet.

    In plain wordsIn adults with obesity and pre-diabetes, carriers of the GLP-1 receptor variant had a weaker glucagon response to liraglutide and diet.

    Peptide
    Liraglutide
    Outcome
    DecreaseResponsiveness of glucagon to liraglutide by genotype
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    individuals with the variant allele exhibited decreased responsiveness to liraglutide and hypocaloric diet in measurements of fasting insulin, C-peptide, glucagon, and HOMA-IR
    1 context sentence
    Summary · context
    Here, we performed a pre-specified analysis of a randomized-controlled trial in individuals with obesity and pre-diabetes comparing treatment with the GLP-1R agonist liraglutide, the dipeptidyl peptidase 4 inhibitor sitagliptin or hypocaloric diet, and evaluated the effects of the rs6923761 variant on outcomes.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and pre-diabetes, rs6923761 variant carriers had decreased responsiveness of HOMA-IR to liraglutide and hypocaloric diet.

    In plain wordsIn adults with obesity and pre-diabetes, carriers of the GLP-1 receptor variant had a weaker HOMA-IR response to liraglutide and diet.

    Peptide
    Liraglutide
    Outcome
    DecreaseResponsiveness of HOMA-IR to liraglutide by genotype
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    individuals with the variant allele exhibited decreased responsiveness to liraglutide and hypocaloric diet in measurements of fasting insulin, C-peptide, glucagon, and HOMA-IR
    1 context sentence
    Summary · context
    Here, we performed a pre-specified analysis of a randomized-controlled trial in individuals with obesity and pre-diabetes comparing treatment with the GLP-1R agonist liraglutide, the dipeptidyl peptidase 4 inhibitor sitagliptin or hypocaloric diet, and evaluated the effects of the rs6923761 variant on outcomes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.